NFKB1 and cancer: Other report supports that acetylation of mutp53 (R158G) through pharmacological agents alters its ability to bind DNA, decreases the oncogenic effect of NF-kB activity, and finally, favors apoptosis, making cancer cells sensitive to DNA-damaging agents.